185 related articles for article (PubMed ID: 31544536)
21. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz M
Haematologica; 2018 Jul; 103(7):1229-1234. PubMed ID: 29674497
[TBL] [Abstract][Full Text] [Related]
22. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
23. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).
Tandon N; Sidana S; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Buadi FK; Fonder AL; Hayman SR; Hwa YL; Hobbs MA; Kapoor P; Gonsalves WI; Leung N; Go RS; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2018 Jan; 93(1):17-22. PubMed ID: 28960427
[TBL] [Abstract][Full Text] [Related]
24. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
Milani P; Basset M; Nuvolone M; Benigna F; Rodigari L; Lavatelli F; Foli A; Merlini G; Palladini G
Blood Cancer J; 2020 Sep; 10(8):90. PubMed ID: 32873771
[TBL] [Abstract][Full Text] [Related]
25. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E; Fotiou D; Theodorakakou F; Dialoupi I; Migkou M; Roussou M; Karatrasoglou EA; Tselegkidi MI; Ntalianis A; Kanellias N; Eleutherakis-Papaiakovou E; Ntanasis-Stathopoulos I; Gakiopoulou C; Papanikolaou A; Papathoma A; Spyropoulou-Vlachou M; Psimenou E; Stamatelopoulos K; Gavriatopoulou M; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):3-11. PubMed ID: 32713209
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Palladini G; Paiva B; Wechalekar A; Massa M; Milani P; Lasa M; Ravichandran S; Krsnik I; Basset M; Burgos L; Nuvolone M; Lecumberri R; Foli A; Puig N; Sesta MA; Bozzola M; Cascino P; Nevone A; Ripepi J; Berti P; Casarini S; Annibali O; Orfao A; San-Miguel J; Merlini G
Blood Cancer J; 2021 Feb; 11(2):34. PubMed ID: 33594045
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.
Rodríguez-Lobato LG; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Aróstegui JI; Rosiñol L; Díaz T; Lozano E; Yagüe J; Bladé J
Amyloid; 2017 Dec; 24(4):245-252. PubMed ID: 29052436
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
[TBL] [Abstract][Full Text] [Related]
29. Detection of minimal residual disease by next generation sequencing in AL amyloidosis.
Sarosiek S; Varga C; Jacob A; Fulciniti MT; Munshi N; Sanchorawala V
Blood Cancer J; 2021 Jun; 11(6):117. PubMed ID: 34155198
[No Abstract] [Full Text] [Related]
30. The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis.
Cohen OC; Law S; Lachmann HJ; Sharpley F; Ravichandran S; Mahmood S; Sachchithanantham S; Whelan CJ; De Azcona Naharro AM; Fontana M; Hawkins PN; Gillmore JD; Wechalekar AD
Blood Cancer J; 2020 May; 10(5):60. PubMed ID: 32444621
[No Abstract] [Full Text] [Related]
31. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
[TBL] [Abstract][Full Text] [Related]
32. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.
Paiva B; Vídriales MB; Pérez JJ; López-Berges MC; García-Sanz R; Ocio EM; de Las Heras N; Cuello R; García de Coca A; Pardal E; Alonso J; Sierra M; Bárez A; Hernández J; Suárez L; Galende J; Mateos MV; San Miguel JF
Blood; 2011 Mar; 117(13):3613-6. PubMed ID: 21266717
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
34. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
36. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.
Palladini G; Jaccard A; Milani P; Lavergne D; Foli A; Bender S; Lavatelli F; Bosoni T; Valentini V; Pirolini L; Ferraro G; Basset M; Russo F; Nuvolone M; Albertini R; Cogne M; Merlini G
Clin Chem Lab Med; 2017 Oct; 55(11):1734-1743. PubMed ID: 28343171
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena MT; Martin-Clavero E; Wong S; Shah N; Bahri N; Alonso R; Barcenas C; Valeri A; Salazar Tabares J; Sanchez-Pina J; Cuellar C; Martin T; Wolf J; Lahuerta JJ; Martinez-Lopez J
PLoS One; 2020; 15(8):e0237155. PubMed ID: 32866200
[TBL] [Abstract][Full Text] [Related]
38. Characterization and prognostic implication of delayed complete response in AL amyloidosis.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Lisa Hwa Y; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Vincent Rajkumar S; Kyle RA; Dispenzieri A
Eur J Haematol; 2021 Mar; 106(3):354-361. PubMed ID: 33230879
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
[TBL] [Abstract][Full Text] [Related]
40. Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Lavatelli F; Nuvolone M; Ferraro G; Palladini G; Merlini G
Amyloid; 2017 Mar; 24(sup1):64-65. PubMed ID: 28434343
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
